ALK Gene Rearrangements in NSCLC for Crizotinib Eligibility by FISH
2006102
Ordering Recommendation
The preferred test for screening for ALK fusion proteins is ALK (D5F3) with Interpretation by Immunohistochemistry (2007324) which is highly concordant with ALK FISH. Use this test if the companion diagnostic test for crizotinib is required.
Submit With Order
Mnemonic
ALK GENE
Methodology
Fluorescence in situ Hybridization
Performed
Varies
Reported
7-10 days
New York DOH Approval Status
This test is New York DOH approved.
Specimen Required
Patient Preparation
 
Collect
Tumor tissue.  
Specimen Preparation
Formalin fix (10 percent neutral buffered formalin) and paraffin embed tumor tissue. Transport tissue block or 4 unstained, consecutively cut, 5-micron thick sections, mounted on positively charged glass slides. (Min: 4 slides) Protect paraffin block and/or slides from excessive heat.  
Storage/Transport Temperature
Room temperature. Also acceptable: Refrigerated.  
Unacceptable Conditions
 
Remarks
Include surgical pathology report with reason for referral. The laboratory will not reject specimens that arrive without a pathology report but will hold the specimen until this information is received.  
Stability
Ambient: Indefinitely; Refrigerated: Indefinitely; Frozen: Unacceptable  
Reference Interval
By report
Interpretive Data
Note
CPT Code(s)
88271 x2, 88274 (25-99), 88291
Components
Component Test Code*Component Chart Name
2006127ALK Gene Rearrangements in NSCL by FISH
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Cross References
  • Lung Cancer, ALK (2p23) Rearrangement, FISH, Tissue
  • Lung Carcinoma
  • Non-Small Cell Lung Cancer
  • NSCLC
  • Soft-FLCA
Performed at Mayo